Clinical research jobs provider Bayer HealthCare has reported findings from a recent study of a Xarelto (rivaroxaban) treatment for acute coronary syndrome patients.
Findings from the phase III Atlas ACS 2-TIMI 51 investigation revealed a combination of twice-daily Xarelto with standard antiplatelet therapy assisted in reducing rates of cardiovascular death, stroke and myocardial infarction among test participants.
The drug was able to meet its primary efficacy endpoint in the trial, which compared the Bayer HealthCare medicine with antiplatelet therapy alone.
Dr Kemal Malik, member of the Bayer HealthCare executive committee and chief medical officer, said: "Acute coronary syndrome is a chronic, life-threatening condition and we believe, based on these data, that rivaroxaban could greatly improve the current standard of care."
This comes after Xarelto received US approval for a treatment to reduce the risk of stroke and systemic embolism among patients suffering from atrial fibrillation.